HYDI: AI 评分 48/100 — AI 分析 (4月 2026)

Hydromer, Inc. specializes in hydrophilic polymer technology, offering coatings and services to medical, cosmetic, and industrial sectors. The company operates through its Polymer Research and Medical Products segments, focusing on patented solutions and contract services.

Key Facts: AI Score: 48/100 Sector: Basic Materials

公司概况

概要：

Hydromer, Inc., founded in 1980, develops and sells hydrophilic polymer-based products and services across medical, cosmetic, and industrial sectors. Operating through Polymer Research and Medical Products segments, the company offers specialized coatings, hydrogels, and contract services, distinguishing itself through patented technologies and diverse applications.

HYDI是做什么的？

Hydromer, Inc., established in 1980, is a technology-driven company focused on inventing, developing, patenting, licensing, manufacturing, and selling hydrophilic polymer-based products and services. The company operates through two primary segments: Polymer Research and Medical Products. Its offerings include medical coatings and services, medical hydrogels, cosmetic intermediaries, and anti-fog/anti-frost condensation control coating products. Hydromer also provides cosmetics and personal care products, along with watercraft hull coating products. Furthermore, Hydromer, Inc. offers engineering and contract coating services, catering to the medical, cosmetics, animal health, and industrial fields. Based in Branchburg, New Jersey, Hydromer serves both domestic and international markets, leveraging its proprietary technologies to deliver specialized solutions. The company's evolution has been marked by a consistent focus on innovation and application of hydrophilic polymers across diverse industries, positioning it as a key player in specialty chemical solutions.

HYDI的投资论点是什么？

Hydromer, Inc. presents a focused investment opportunity within the specialty chemicals sector, driven by its patented hydrophilic polymer technology. The company's diverse applications across medical, cosmetic, and industrial fields provide revenue streams. A key value driver is the expansion of its medical coatings and services segment, targeting a growing market for biocompatible materials. The company's current negative P/E ratio of -0.59 and a negative profit margin of -42.8% indicate potential for turnaround through strategic partnerships and cost optimization. Growth catalysts include increased licensing agreements and expansion of contract coating services. Investors should monitor gross margin improvements from its current 48.9% and beta of -0.93.

HYDI在哪个行业运营？

Hydromer, Inc. operates within the specialty chemicals industry, which is characterized by innovation and customized solutions. The market is driven by demand for high-performance materials in sectors like healthcare, cosmetics, and industrial coatings. Key trends include a focus on biocompatibility, sustainability, and advanced material science. Hydromer competes with companies like CBNT, GBGD, GPHBF, INTK, and MGIDF, which offer similar specialty chemical products and services. The industry is experiencing growth in demand for specialized coatings and hydrogels, creating opportunities for companies with patented technologies and strong customer relationships.

Chemicals - Specialty

Basic Materials

HYDI有哪些增长机遇？

Expansion of Medical Coatings and Services: The market for medical coatings is growing due to increasing demand for biocompatible materials in medical devices. Hydromer can capitalize on this by expanding its range of medical coatings and services, targeting a market estimated at $15 billion by 2028. A focus on innovative coatings for implantable devices and drug delivery systems could drive significant revenue growth.
Increased Licensing Agreements: Hydromer's patented hydrophilic polymer technology can be leveraged through licensing agreements with other companies in the medical, cosmetic, and industrial sectors. This provides a low-risk revenue stream and expands the reach of its technology. Securing 2-3 new licensing agreements annually could generate substantial royalty income.
Growth in Cosmetic Intermediaries: The demand for specialized ingredients in the cosmetics industry is increasing, driven by consumer demand for high-performance products. Hydromer can expand its offerings of cosmetic intermediaries, targeting a market estimated at $40 billion by 2027. Developing new hydrogel-based ingredients for skincare and haircare products could drive significant growth.
Expansion of Contract Coating Services: Hydromer can leverage its expertise in coating technology to offer contract coating services to companies in various industries. This provides a stable revenue stream and allows the company to utilize its manufacturing facilities efficiently. Targeting industries such as automotive, aerospace, and electronics could drive growth in this segment.
Development of Anti-Fog/Anti-Frost Coatings: The market for anti-fog and anti-frost coatings is growing, driven by demand for improved visibility and safety in various applications. Hydromer can expand its offerings in this area, targeting industries such as automotive, aerospace, and consumer electronics. Developing new coatings with enhanced durability and performance could drive significant revenue growth.

Operates in two segments: Polymer Research and Medical Products, focusing on hydrophilic polymer technology.
Offers a diverse range of products including medical coatings, cosmetic intermediaries, and anti-fog coatings.
Serves multiple sectors including medical, cosmetics, animal health, and industrial.
Gross margin of 48.9% indicates strong potential for profitability with optimized operations.
Negative Beta of -0.93 suggests the stock price is less volatile than the market average.

HYDI提供哪些产品和服务？

Invents and develops hydrophilic polymer-based products.
Patents and licenses its proprietary technologies.
Manufactures and sells medical coatings and services.
Offers medical hydrogels for various applications.
Provides cosmetic intermediaries for personal care products.
Supplies anti-fog and anti-frost condensation control coatings.
Offers engineering and contract coating services.

HYDI如何赚钱？

Develops and patents hydrophilic polymer technologies.
Manufactures and sells specialized coatings and hydrogels.
Licenses its technologies to other companies.
Provides contract coating services to various industries.

Medical device manufacturers
Cosmetic and personal care product companies
Industrial companies requiring specialized coatings
Animal health product manufacturers

Patented hydrophilic polymer technologies
Specialized expertise in coating applications
Long-standing relationships with customers in key industries
Proprietary formulations and manufacturing processes

什么因素可能推动HYDI股价上涨？

Ongoing: Expansion of medical coatings and services segment driven by increasing demand for biocompatible materials.
Ongoing: Increased licensing agreements for patented hydrophilic polymer technology.
Upcoming: Potential partnerships with larger companies in the medical and cosmetic sectors by Q4 2026.
Ongoing: Growth in cosmetic intermediaries segment due to consumer demand for high-performance products.
Ongoing: Expansion of contract coating services to new industries such as automotive and aerospace.

HYDI的主要风险是什么？

Potential: Competition from larger chemical companies with greater resources and market share.
Ongoing: Dependence on key patents and the risk of patent infringement.
Potential: Economic downturn affecting demand for specialty chemical products.
Ongoing: Limited financial resources and potential need for additional funding.
Potential: Regulatory changes impacting the use of certain chemicals or coatings.

HYDI的核心优势是什么？

Patented hydrophilic polymer technology
Diverse applications across multiple industries
Specialized expertise in coating applications
Established relationships with key customers

HYDI的劣势是什么？

Negative profit margin
Limited financial resources
Small employee base
Dependence on key patents

HYDI有哪些机遇？

Expansion into new markets and applications
Increased licensing agreements
Strategic partnerships with larger companies
Growing demand for biocompatible materials

HYDI面临哪些威胁？

Competition from larger chemical companies
Patent infringement
Economic downturn
Regulatory changes

HYDI的竞争对手是谁？

Canna-Biz Technologies — Focuses on cannabis-related technologies. — (CBNT)
Green Bridge Gold Corp. — Operates in the gold mining sector. — (GBGD)
Graphite Bio Inc — Develops next-generation gene editing therapies. — (GPHBF)
Intellinetics Inc — Specializes in document management and workflow solutions. — (INTK)
MGID Inc — Provides native advertising solutions. — (MGIDF)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Michael Torti
Headquarters: Branchburg, US
Employees: 34
Founded: 1999

AI Insight

AI analysis pending for HYDI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Hydromer, Inc. do?

Hydromer, Inc. invents, develops, and manufactures hydrophilic polymer-based products, operating through Polymer Research and Medical Products segments. They provide medical coatings, hydrogels, cosmetic intermediaries, and anti-fog coatings. Additionally, Hydromer offers contract coating services, serving the medical, cosmetics, animal health, and industrial sectors. Their core business revolves around patented technologies and specialized chemical solutions, targeting niche markets with high-performance material demands.

What do analysts say about HYDI stock?

As of 2026-03-15, formal analyst ratings for HYDI are unavailable due to its OTC listing and limited coverage. Key valuation metrics include a negative P/E ratio of -0.59 and a gross margin of 48.9%. Growth considerations center on expanding medical coatings and licensing agreements. Investors should monitor financial disclosures and industry trends to assess the company's potential, noting the inherent risks associated with OTC-listed companies and the absence of analyst consensus.

What are the main risks for HYDI?

Hydromer, Inc. faces several risks, including competition from larger chemical companies, dependence on key patents, and potential economic downturns affecting demand. As an OTC-listed company, HYDI is subject to limited financial disclosure and regulatory oversight, increasing the risk of fraud or manipulation. Low trading volume and liquidity can lead to price volatility. Investors should carefully assess these factors before investing, considering the company's financial health and market position.